Suzhou MedicalSystem Technology (603990) Fundamentals 2026 — P/E 269.6x, Revenue Analysis | SniperIQ
Suzhou MedicalSystem Technology (603990) is a CN-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ¥5.1B, trading at ¥16.77 on the SHH. This SniperIQ fundamentals page covers Suzhou MedicalSystem Technology's valuation (P/E 269.6x, P/B 6.1x), profitability (net margin 6.5%), revenue (¥300M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Suzhou MedicalSystem Technology's market cap?
Suzhou MedicalSystem Technology (603990) has a market capitalization of approximately ¥5.1B, trading at ¥16.77 on the SHH. Market cap moves with the live share price.
What is Suzhou MedicalSystem Technology's P/E ratio?
Suzhou MedicalSystem Technology's trailing twelve-month P/E ratio is 269.6x, with a price-to-book (P/B) of 6.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Suzhou MedicalSystem Technology?
Suzhou MedicalSystem Technology runs a net profit margin of 6.5%, a gross margin of 57.6%, and an operating margin of 7.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Suzhou MedicalSystem Technology generate?
Suzhou MedicalSystem Technology reported revenue of ¥300M for fiscal year 2025, with net income of ¥39M and earnings per share (EPS) of 0.13. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Suzhou MedicalSystem Technology pay a dividend?
Suzhou MedicalSystem Technology does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Suzhou MedicalSystem Technology financially healthy?
Suzhou MedicalSystem Technology carries a debt-to-equity ratio of 0.31x and a current ratio of 2.35x, with a market beta of 0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Suzhou MedicalSystem Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Suzhou MedicalSystem Technology (603990) the key facts are: market cap ¥5.1B, P/E 269.6x, revenue ¥300M, 52-week range 13.74-23.69. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Suzhou MedicalSystem Technology's full fundamentals live
Get Suzhou MedicalSystem Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.